Martínez-Fleta, Pedro
Vicente-Rabaneda, Esther F. http://orcid.org/0000-0001-6823-4194
Triguero-Martínez, Ana
Roy-Vallejo, Emilia
Uriarte-Ecenarro, Miren
Gutiérrez-Rodríguez, Francisco
Quiroga-Colina, Patricia
Romero-Robles, Ana
Montes, Nuria
García-Castañeda, Noelia
Mejía-Abril, Gina P. http://orcid.org/0000-0002-8689-7941
García-Vadillo, Jesús A.
Llorente-Cubas, Irene
Villagrasa, José R.
Serra López-Matencio, José M. http://orcid.org/0000-0003-1786-7535
Ancochea, Julio
Urzainqui, Ana
Esparcia-Pinedo, Laura
Alfranca, Arantzazu
de la Fuente, Hortensia
García-Vicuña, Rosario
Sánchez-Madrid, Francisco
González-Álvaro, Isidoro http://orcid.org/0000-0001-9614-5199
Castañeda, Santos http://orcid.org/0000-0002-7748-853X
Article History
Received: 20 June 2023
Accepted: 2 January 2024
First Online: 30 January 2024
Competing interests
: S.C. has received consultation fees in company-sponsored speaker’s bureau from Amgen, BMS, Eli-Lilly, MSD, Roche, Sanofi and UCB. S. Castañeda is assistant professor of the cátedra UAM-Roche, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. I.G.-A. reports grants from Instituto de Salud Carlos III, during the course of the study; personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The rest of the authors do not declare conflicts of interest in relation to this work.